A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Key facts

Sponsor

Shanghai Jiaolian Drug Research and Development Co., Ltd

Intervention

B013(drug)

Enrollment

90 target

Eligibility

18-75 years · FEMALE

Timeline

2024 – 2026

Study locations (17)

• Beijing Cancer Hospital, Beijing, China
• The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
• XiangYa Hospital CentralSouth University, Changsha, China
• Fujian Cancer Hospital, Fuzhou, China
• Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
• Cancer Hospital of Shandong First Medical University, Jinan, China
• Qilu Hospital of Shandong University, Jinan, China
• Yunnan Cancer Hospital, Kunming, China
• Guangxi Medical University Cancer Hospital, Nanning, China
• Fudan University Shanghai Cancer center, Shanghai, China
• The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China
• The Second Hospital of Hebei Medical University, Shijiazhuang, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
• Shananxi Provincial Cancer Hospital, Xi'an, China
• The First Affiliated Hospital of Xiamen University, Xiamen, China
• +2 more locations on ClinicalTrials.gov

Collaborators

Shanghai Pharmaceuticals Holding Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary peritoneal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07480954
  Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07322094
  CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
  TORL Biotherapeutics, LLC
• RECRUITINGPHASE3NCT06915025
  Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
  Imunon
• RECRUITINGPHASE2NCT07023484
  Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
  The University of Hong Kong
• RECRUITINGPHASE2NCT06639074
  Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
  Mayo Clinic
• RECRUITINGPHASE1NCT06469281
  A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
  Regeneron Pharmaceuticals
• RECRUITINGPHASE2NCT06492070
  Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
  Emory University
• RECRUITINGPHASE2NCT06420973
  RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
  Peking University Cancer Hospital & Institute

See all trials for Primary peritoneal carcinoma →